Printed From BioPortfolio.com

Lilly’s Abemaciclib Fails to Improve Survival in Late-Stage Trial in Patients with KRAS-Positive NSCLC

09:27 EDT 11 Oct 2017 | Speciality Pharma Journal

INDIANAPOLIS, Oct. 10, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 JUNIPER study evaluating Verzenio™ (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced non-small lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS). However, an analysis of the secondary study endpoints of both …

Original Article: Lilly’s Abemaciclib Fails to Improve Survival in Late-Stage Trial in Patients with KRAS-Positive NSCLC

More From BioPortfolio on "Lilly’s Abemaciclib Fails to Improve Survival in Late-Stage Trial in Patients with KRAS-Positive NSCLC"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches